Register at: https://www.cvent.com/events/cell-gene-therapies-101/registration-5c43450eb0aa417e80dd2d55542ab792.aspx?fqp=true
Careers | Centre for Commercialization of Regenerative Medicine | Article
Role Summary: We are seeking a Manager, Commercialization. You will be the point person for providing and coordinating customized commercialization advice and support to university-based Principal I...
Making connections - advancing regenerative medicine through partnerships - Signals Blog
A key driver for advancements in regenerative medicine is partnerships. In recognition of this, every year CCRM hosts a networking reception that brings together our partners for an evening of discussion and knowledge sharing. This year's industry networking reception was focused on the theme of increasing partnerships between industry and academia.
The Drug of the Future: Cells
Bioengineers are seeking to manufacture enough stem cells to make therapies viable, with big potential payoffs in fighting disease. READ MORE: http://researc...
Special op/ed: Canada can lead the world in regenerative medicine - but it won't happen without strategic investment - Signals Blog
Michael May is President and CEO of CCRM, a leader in developing and commercializing regenerative medicine, cell and gene therapy technologies, Michael Rudnicki is Scientific Director and CEO of Stem Cell Network, with a mandate to translate stem cell research into clinical applications, commercial products and public policy, and Peter Zandstra is a professor in the Institute of Biomaterials & Biomedical Engineering and Executive Director of Medicine by Design at the University of Toronto.
Doctors’ Notes: Why scientific breakthroughs take time to move from lab to bedside | Toronto Star
Studies often produce a lot of hope, but also frustration that the “product” is not available to patients.